Drug Trial Radar · NCT07827027
Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Sep 21, 2026
Primary completion
Nov 5, 2026
Study completion Dec 2, 2026
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, open, parallel-designed bioequivalence study aimed at evaluating the pharmacokinetic differences of RAY1225 injection after site and batch changes compared to before the changes.
Conditions
- Basic Science
Interventions
RAY1225Drug
Single subcutaneous injection of RAY1225 3mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t])Time frame: Baseline through Day 43
- PK: Maximum Concentration of RAY1225Time frame: Baseline through Day 43
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.